Identification of a novel human B cell activation antigen involved in B cell growth factor-dependent proliferation

Chien-Te Tseng, C. F. Springgate, W. Tadmori, Y. S. Choi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The B6.4 mAb we present here identifies a novel activation Ag of B cell lineage. The B6.4 mAb was generated by immunizing mice with B cell growth factor (BCGF)-responding BA3 cells, and selected by its capability to block BCGF-induced proliferation of BA3 cells. The inhibitory effect of this antibody on BCGF-dependent proliferation was further confirmed by using normal activated B cells in the presence of exogenous BCGF derived from T cells or B cells. Furthermore, it did not affect IL-2-dependent proliferation of B cells. The expression of the B6.4 Ag, as analyzed by FACS, is restricted to in vitro activated B cells, and remains undetectable on resting B or T cells, PHA-activated T cells, and monocytes. The B6.4 Ag is also expressed on some lymphoblastoid B cell lines and most of the lymphomas and CLL of B cell origin: however, it did not express on pre-B cell ALL and plasma cell leukemia. The B6.4 Ag has a M(r) of 35,000 Da, as determined by SDS-PAGE or radiolabeled immunoprecipitates from activated B cells. The B6.4 Ag is detectable on B cells as early as 8 h after activation, and precedes that of the IL-2R or transferrin R. All of these results suggest that the B6.4 Ag is an early activation Ag of B cells and is functionally related to a receptor of BCGF, but not IL-2.

Original languageEnglish (US)
Pages (from-to)2305-2311
Number of pages7
JournalJournal of Immunology
Volume140
Issue number7
StatePublished - 1988
Externally publishedYes

Fingerprint

CD80 Antigens
Intercellular Signaling Peptides and Proteins
B-Lymphocytes
Interleukin-2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Plasma Cell Leukemia
T-Lymphocytes
B-Lymphoid Precursor Cells

ASJC Scopus subject areas

  • Immunology

Cite this

Identification of a novel human B cell activation antigen involved in B cell growth factor-dependent proliferation. / Tseng, Chien-Te; Springgate, C. F.; Tadmori, W.; Choi, Y. S.

In: Journal of Immunology, Vol. 140, No. 7, 1988, p. 2305-2311.

Research output: Contribution to journalArticle

@article{5e433bbca3794ced8612465d0085e543,
title = "Identification of a novel human B cell activation antigen involved in B cell growth factor-dependent proliferation",
abstract = "The B6.4 mAb we present here identifies a novel activation Ag of B cell lineage. The B6.4 mAb was generated by immunizing mice with B cell growth factor (BCGF)-responding BA3 cells, and selected by its capability to block BCGF-induced proliferation of BA3 cells. The inhibitory effect of this antibody on BCGF-dependent proliferation was further confirmed by using normal activated B cells in the presence of exogenous BCGF derived from T cells or B cells. Furthermore, it did not affect IL-2-dependent proliferation of B cells. The expression of the B6.4 Ag, as analyzed by FACS, is restricted to in vitro activated B cells, and remains undetectable on resting B or T cells, PHA-activated T cells, and monocytes. The B6.4 Ag is also expressed on some lymphoblastoid B cell lines and most of the lymphomas and CLL of B cell origin: however, it did not express on pre-B cell ALL and plasma cell leukemia. The B6.4 Ag has a M(r) of 35,000 Da, as determined by SDS-PAGE or radiolabeled immunoprecipitates from activated B cells. The B6.4 Ag is detectable on B cells as early as 8 h after activation, and precedes that of the IL-2R or transferrin R. All of these results suggest that the B6.4 Ag is an early activation Ag of B cells and is functionally related to a receptor of BCGF, but not IL-2.",
author = "Chien-Te Tseng and Springgate, {C. F.} and W. Tadmori and Choi, {Y. S.}",
year = "1988",
language = "English (US)",
volume = "140",
pages = "2305--2311",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Identification of a novel human B cell activation antigen involved in B cell growth factor-dependent proliferation

AU - Tseng, Chien-Te

AU - Springgate, C. F.

AU - Tadmori, W.

AU - Choi, Y. S.

PY - 1988

Y1 - 1988

N2 - The B6.4 mAb we present here identifies a novel activation Ag of B cell lineage. The B6.4 mAb was generated by immunizing mice with B cell growth factor (BCGF)-responding BA3 cells, and selected by its capability to block BCGF-induced proliferation of BA3 cells. The inhibitory effect of this antibody on BCGF-dependent proliferation was further confirmed by using normal activated B cells in the presence of exogenous BCGF derived from T cells or B cells. Furthermore, it did not affect IL-2-dependent proliferation of B cells. The expression of the B6.4 Ag, as analyzed by FACS, is restricted to in vitro activated B cells, and remains undetectable on resting B or T cells, PHA-activated T cells, and monocytes. The B6.4 Ag is also expressed on some lymphoblastoid B cell lines and most of the lymphomas and CLL of B cell origin: however, it did not express on pre-B cell ALL and plasma cell leukemia. The B6.4 Ag has a M(r) of 35,000 Da, as determined by SDS-PAGE or radiolabeled immunoprecipitates from activated B cells. The B6.4 Ag is detectable on B cells as early as 8 h after activation, and precedes that of the IL-2R or transferrin R. All of these results suggest that the B6.4 Ag is an early activation Ag of B cells and is functionally related to a receptor of BCGF, but not IL-2.

AB - The B6.4 mAb we present here identifies a novel activation Ag of B cell lineage. The B6.4 mAb was generated by immunizing mice with B cell growth factor (BCGF)-responding BA3 cells, and selected by its capability to block BCGF-induced proliferation of BA3 cells. The inhibitory effect of this antibody on BCGF-dependent proliferation was further confirmed by using normal activated B cells in the presence of exogenous BCGF derived from T cells or B cells. Furthermore, it did not affect IL-2-dependent proliferation of B cells. The expression of the B6.4 Ag, as analyzed by FACS, is restricted to in vitro activated B cells, and remains undetectable on resting B or T cells, PHA-activated T cells, and monocytes. The B6.4 Ag is also expressed on some lymphoblastoid B cell lines and most of the lymphomas and CLL of B cell origin: however, it did not express on pre-B cell ALL and plasma cell leukemia. The B6.4 Ag has a M(r) of 35,000 Da, as determined by SDS-PAGE or radiolabeled immunoprecipitates from activated B cells. The B6.4 Ag is detectable on B cells as early as 8 h after activation, and precedes that of the IL-2R or transferrin R. All of these results suggest that the B6.4 Ag is an early activation Ag of B cells and is functionally related to a receptor of BCGF, but not IL-2.

UR - http://www.scopus.com/inward/record.url?scp=0023893712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023893712&partnerID=8YFLogxK

M3 - Article

C2 - 2450917

AN - SCOPUS:0023893712

VL - 140

SP - 2305

EP - 2311

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -